Continuing Medical Education
Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Imedex, LLC designates this live educational activity for a maximum 18.5 of AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Who Should Attend
This educational activity is specifically designed for hematologists, oncologists, and other physicians, clinicians, physiciansin- training, and healthcare professionals involved and/or interested in the therapeutic management of patients with lymphoproliferative and other plasma cell disorders.
After attending this conference, participants should be able to:
- Have increased awareness/knowledge regarding:
- Biological pathways in hematological malignances and their therapeutic implications
- The biology of bone disease in myeloma and the evolving role of bisphosphonates and other anti-RANKL agents in patient care
- The implications of recent clinical investigations into improving standard therapy for lymphoma and other hematological malignancies
- Novel therapies on the horizon, including HDAC inhibitors, new generation IMiDs, and proteasome inhibitors, and how to best use them in lymphoma and myeloma
- Have increased confidence in their ability to:
- Address challenging issues surrounding the use of transplantation including determining which patients it would benefit, optimal timing, and whether it is necessary as frontline therapy in myeloma
- Adequately evaluate clinical situations in which maintenance therapy should be used in myeloma and lymphoma
- Create optimal therapeutic plans for younger and elderly patients with CLL
- Evaluate the potential of new treatment strategies for relapsed aggressive lymphoma for recent clinical investigations for both transplant-eligible and ineligible patients
- Increased their planned (compared with current) frequency of use of:
- Enrollment in clinical trials of promising novel agents for hematologic malignancies